US · ARAY
Accuray Incorporated
- Sector
- Healthcare · Medical - Devices
- Headquarters
- Madison, WI 53717-1954
- Website
- accuray.com
Price · as of 2025-06-30
$0.47
Market cap 68.6M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $30.97 | +6,535.95% |
| Intrinsic Value(DCF) | $0.60 | +28.56% |
| Graham-Dodd Method(GD) | $0.15 | -67.86% |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $4.30 | $112.92 | $132.86 | $0.70 | $0.00 |
| 2012 | $5.84 | $89.10 | $2,020.68 | $0.00 | $0.00 |
| 2013 | $6.46 | $23.80 | $0.00 | $0.00 | $19.29 |
| 2014 | $7.84 | $35.73 | $26.95 | $0.00 | $0.00 |
| 2015 | $6.60 | $903.71 | $0.00 | $0.00 | $0.00 |
| 2016 | $5.35 | $61.42 | $0.01 | $0.00 | $0.00 |
| 2017 | $4.15 | $30.42 | $0.00 | $0.00 | $0.00 |
| 2018 | $3.80 | $840.10 | $0.00 | $0.00 | $0.00 |
| 2019 | $2.82 | $49.58 | $0.00 | $0.00 | $0.00 |
| 2020 | $2.25 | $32.20 | $0.00 | $0.28 | $0.00 |
| 2021 | $3.66 | $468.06 | $0.16 | $0.00 | $0.00 |
| 2022 | $2.38 | $31.49 | $0.00 | $0.00 | $0.00 |
| 2023 | $2.63 | $124.11 | $0.00 | $0.00 | $0.00 |
| 2024 | $1.92 | $35.68 | $0.00 | $0.00 | $0.00 |
| 2025 | $1.51 | $30.97 | $0.00 | $0.15 | $0.00 |
AI valuation
Our deep-learning model estimates Accuray Incorporated's (ARAY) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $30.97
- Current price
- $0.47
- AI upside
- +6,535.95%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$0.60
+28.56% upside
Graham-Dodd
$0.15
-67.86% upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| ARAY | Accuray Incorporated | $0.47 | 68.6M | +6,536% | +29% | -68% | — | -97.54 | 1.91 | 0.34 | 13.55 | — | 6.65 | 32.05% | 1.71% | -0.35% | -2.52% | 1.62% | -0.34% | 2.17 | 0.61 | 1.65 | 0.81 | 5.88 | -9031.00% | 268.00% | -6348.00% | -3.65% | 0.01 | -2.92% | 0.00% | 0.00% | 14.96% | 34.97 | -48.41 | 0.60 | 0.04 |
| ANIK | Anika Therapeutics, Inc. | $14.36 | 207.09M | +157% | -53% | -61% | — | -18.87 | 1.43 | 1.82 | -93.81 | — | 1.54 | 56.56% | -9.80% | -9.64% | -7.32% | -9.43% | -5.54% | 0.17 | -6.34 | 4.72 | 3.71 | 18.15 | -8016.00% | -591.00% | -28713.00% | 2.12% | 0.51 | 3.72% | 0.00% | 0.00% | 6.37% | -15.57 | 39.44 | 1.53 | 3.99 |
| AVR | Anteris Technologies Glob… | $6.51 | 239.49M | +229% | -58% | — | +1,116% | -1.66 | -1678.27 | 81.59 | -1.58 | -27.15 | -987.84 | 70.26% | 24.41% | -4925.51% | -300.71% | -5.60% | -181.73% | -24.54 | 6.40 | 0.73 | 0.59 | 0.11 | 610.00% | -2923.00% | 2251.00% | -49.85% | -3.64 | 932.39% | 0.00% | 0.00% | 0.00% | 312.17 | -1.87 | 76.21 | -18.68 |
| LNSR | LENSAR, Inc. | $11.97 | 142.98M | +705% | -42% | — | — | -5.45 | 9.18 | 3.20 | -50.35 | -5.03 | 13.66 | 48.33% | -19.94% | -58.71% | -95.42% | -88.05% | -46.22% | 0.14 | — | 2.80 | 1.93 | 4.54 | 10840.00% | 2687.00% | -7543.00% | -1.42% | -0.15 | -20.07% | 0.00% | 0.00% | 0.00% | -14.19 | -62.24 | 2.83 | -0.11 |
| MIST | Milestone Pharmaceuticals… | $1.71 | 145.64M | +1,960% | — | — | — | -2.76 | 8.71 | — | -2.63 | — | 8.71 | 0.00% | — | — | -277.55% | -10631.82% | -55.09% | 4.17 | 11.76 | 9.10 | 8.87 | -0.78 | -5180.00% | -10000.00% | -3794.00% | -25.23% | -3.55 | -7293.18% | 0.00% | 0.00% | 7.45% | -2.36 | -3.45 | — | -6.51 |
| MXCT | MaxCyte, Inc. | $0.81 | 86.54M | +3,073% | +164% | -99% | — | -8.96 | 1.78 | 9.53 | -4.99 | -165.84 | 1.78 | 81.62% | -132.54% | -106.29% | -18.73% | -67.18% | -16.17% | 0.09 | — | 10.88 | 10.09 | 0.21 | 541.00% | -644.00% | 1526.00% | -7.95% | -1.75 | -38.39% | 0.00% | 0.00% | 0.00% | -4.52 | -7.91 | 6.00 | 5.62 |
| OWLT | Owlet, Inc. | $11.55 | 184.81M | +401% | +393% | — | — | -5.81 | -3.44 | 0.93 | -6.80 | — | -3.29 | 50.36% | -25.90% | -16.06% | 49.33% | 68.11% | -26.78% | -0.56 | -12.40 | 1.27 | 0.89 | 0.88 | -8168.00% | 4452.00% | -4925.00% | -16.44% | -0.31 | 40.32% | 0.00% | 0.00% | 11.27% | -3.19 | -5.38 | 0.83 | -6.50 |
| PROF | Profound Medical Corp. | $7.61 | 229.84M | +279% | -61% | — | — | -6.11 | 2.81 | 16.71 | -4.69 | — | 2.82 | 65.89% | -309.57% | -260.45% | -60.70% | -267.75% | -48.72% | 0.08 | — | 10.52 | 9.44 | 1.95 | -2074.00% | 4123.00% | 373.00% | -13.80% | -3.57 | -199.52% | 0.00% | 0.00% | 18.51% | -3.82 | -5.12 | 11.81 | 5.24 |
| RANI | Rani Therapeutics Holding… | $1.37 | 100M | — | -55% | — | — | -0.79 | 22.30 | 43.21 | -0.92 | — | 22.30 | 100.00% | -5186.19% | -2920.04% | -761.66% | 7052.12% | -119.69% | 14.91 | -10.59 | 1.50 | 1.41 | -0.51 | -2105.00% | — | -3183.00% | -80.51% | -1.78 | 4730.69% | 0.00% | 0.00% | 0.00% | -0.87 | -1.30 | 45.23 | -7.58 |
| RPID | Rapid Micro Biosystems, I… | $4.33 | 191.92M | +463% | -78% | — | — | -2.22 | 1.38 | 3.71 | -1.28 | — | 1.38 | -0.39% | -177.96% | -167.16% | -48.50% | -155.83% | -38.81% | 0.08 | — | 4.61 | 3.32 | 0.23 | -1148.00% | 2457.00% | -300.00% | -43.71% | -2.51 | -142.09% | 0.00% | 0.00% | 0.00% | -1.19 | -1.31 | 2.12 | -4.66 |
| TLSI | TriSalus Life Sciences, I… | $5.06 | 167.17M | +547% | +1,763% | — | — | -4.73 | -5.49 | 4.83 | -4.35 | — | -5.49 | 86.06% | -122.88% | -112.92% | 113.47% | 150.57% | -123.72% | -0.91 | -11.70 | 2.02 | 1.33 | -0.42 | -4395.00% | 5899.00% | -1950.00% | -29.00% | -3.99 | 171.48% | 0.00% | 0.00% | 0.00% | -4.35 | -3.82 | 5.34 | -17.85 |
About Accuray Incorporated
Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, China, and rest of the Asia Pacific region. It offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. The company also provides the TomoTherapy System, including the Radixact System, which allows for integrated radiation treatment planning, delivery, and data management, enabling clinicians to deliver ultra-precise treatments to approximately 50 patients per day; iDMS data management system, a fully integrated treatment planning and data management systems; and Accuray precision treatment planning system, a treatment planning and data management systems. In addition, it offers post-contract customer support, installation, training, and other professional services. The company primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Madison, Wisconsin.
- CEO
- Stephen R. LaNeve
- Employees
- 987
- Beta
- 1.15
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($0.60 ÷ $0.47) − 1 = +28.56% (DCF, example).